Petmed Express Inc

Petmed Express Inc (PETS) Stock Analysis

$1.880

+0.030 (+1.62%)At close

Loading chart…
High
1.925
Open
1.830
VWAP
1.88
Vol
70.03K
Mkt Cap
86.14M
Low
1.830
Amount
131.54K
EV/EBITDA, TTM
-1.50

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

AI analysis of Petmed Express Inc (PETS)

hold

PetMed Express Inc is currently trading at $1.88, which is significantly below the proposed acquisition price of $3.00 per share by SilverCape Investments. However, the company has reported a negative net income of -$6,145,000 for the last quarter, indicating ongoing financial struggles. The RSI is at 65.325, suggesting the stock is nearing overbought territory, while insiders have increased their buying activity by 174.01%, which could signal confidence in the company's future. Given these mixed signals, it may be prudent to hold rather than buy at this time.

Analyst Ratings (5)

Buy
2 Buy
2 Hold
1 Sell
Current: 1.88
Low
Average
High

Morgan Stanley

2025-04-17

Price Target

$3.2

Sell

Lake Street

2024-08-07

Price Target

$3.5

Hold

Morgan Stanley

2024-06-12

Price Target

$3.5

Sell

Lake Street

2024-06-12

Price Target

$7

Strong Buy

Lake Street

2024-02-09

Price Target

$9

Strong Buy

Valuation Metrics

The current forward P/E ratio for Petmed Express Inc (PETS) is 16.69, compared to its 5-year average forward P/E of -10.06.

Forward P/E

Fair
5Y Average P/E
-10.06
Current P/E
16.69
Overvalued
97.29
Undervalued
-117.41

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
8.19
Current EV/EBITDA
-1.50
Overvalued
14.75
Undervalued
1.64

Forward P/S

Fair
5Y Average P/S
0.81
Current P/S
0.22
Overvalued
1.42
Undervalued
0.20

Alphio AI Price Scenarios for PETS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PETS

$4.12

Scenario price

B

Base

Base · 50%PETS

$3.76

Scenario price

B

Bear

Bear · 25%PETS

$3.08

Scenario price

Whales holding PETS

O

Oaktop Capital Management II, L.P.

+ HoldingPETS

-7.01%

3M Return

Events Timeline

2026-07-23 (ET)

08:30:00

PetMed Express Enters $37M Sale-Leaseback Agreement with Investor

2026-06-30 (ET)

10:00:00

PetMed Express Receives $3.00 Acquisition Proposal from SilverCape

2026-06-29 (ET)

09:30:00

Nasdaq Futures Rise, PetMed Express Stock Soars 32%

08:00:00

SilverCape Proposes to Acquire PetMed at $3.00 per Share

2026-06-02 (ET)

19:30:00

Utilities and Basic Materials Propel S&P 500 to New Record Highs

News

PETS FAQ — answered by Alphio AI

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

PetMed Express Inc is currently trading at $1.88, which is significantly below the proposed acquisition price of $3.00 per share by SilverCape Investments. However, the company has reported a negative net income of -$6,145,000 for the last quarter, indicating ongoing financial struggles. The RSI is at 65.325, suggesting the stock is nearing overbought territory, while insiders have increased their buying activity by 174.01%, which could signal confidence in the company's future. Given these mixed signals, it may be prudent to hold rather than buy at this time.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten